{'fraction_non_alphanumeric': 0.011656952539550375, 'fraction_numerical': 0.0016652789342214821, 'mean_word_length': 5.427807486631016, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Role of clonal gemopoeisis in development of individual approaches for early diagnostics, treatment and rehabilitation of patients with cardio-vascular diseases

Recently, due to significant improvement and cheapening of the new generation of full genome sequencing technology, it has become possible to identify acquired mutations in individual cells of the hematopoietic system. This has led to the detection of clones of hematopoietic cells with acquired mutations in certain genes in middle-aged and elderly people and made it possible to characterize a new prepathological state - clonal hemopoiesis. Clonal hemopoiesis is defined as the appearance and clonal expansion of cells of the hemopoietic system with genetic changes that give these cells certain advantages in proliferation and/or resistance to adverse factors in comparison with other hemopoietic cells. This phenomenon is found mainly in individuals after 55 years of age and is practically not found in individuals of young age. At this age, most individuals show signs of cardiovascular pathology of some degree of severity. This review discusses some aspects of the possible impact of clonal hemopoiesis on cardiovascular diseases.